Urolithin A for Perimenopause: Energy & Muscle Support

Perimenopause can bring a frustrating mix of lower energy and a sense that your muscles are not what they were. Urolithin A is often mentioned in this conversation — so here is the careful truth: it is not a hormone therapy and has never been tested specifically in perimenopausal women, but its human research on muscle and cellular energy is relevant to concerns many women in this stage share.

Setting expectations honestly

Before anything else: no urolithin A trial to date was designed around perimenopause, and none measured menopausal symptoms, hormones, hot flashes, or bone density. So we cannot say urolithin A does anything for perimenopause as a condition, and we will not make hormone claims. What we can do is explain why women navigating this stage often land on urolithin A — and then show exactly what the research supports and what it does not. For the compound itself, start with our urolithin A guide.

What changes in perimenopause — and why muscle and energy come up

Perimenopause is the transitional years before menopause, when estrogen levels fluctuate and gradually decline. This shift touches many systems, but two complaints are especially common: dropping energy and changes in muscle. There is a physiological reason both surface at once. Estrogen influences muscle tissue, and research on the musculoskeletal system describes how declining estrogen is associated with reduced muscle strength and a faster tilt toward age-related muscle loss (sarcopenia). At the same time, muscle is one of the body's most mitochondria-rich, energy-hungry tissues — so when muscle quality and cellular energy dip together, the felt result is often fatigue plus a loss of physical capacity.

This is the honest bridge to urolithin A: not that it addresses menopause, but that the muscle-and-energy territory women describe in perimenopause overlaps with the exact endpoints urolithin A has been studied on. That overlap is worth understanding — with the caveat that overlap in topic is not the same as proof in this population.

How urolithin A works

Urolithin A is a gut postbiotic. You do not absorb much of it directly from food; your gut bacteria make it from ellagitannins — compounds in pomegranates, walnuts, and some berries — in a multi-step conversion that varies widely between individuals. Only a minority of people produce meaningful amounts on their own, which is why the finished molecule is taken as a supplement. Its best-established action is supporting mitophagy: the cellular cleanup process that recycles worn-out mitochondria so healthier ones can take over. Because muscle depends so heavily on mitochondria, this is the mechanistic reason urolithin A's research has centered on muscle and cellular energy. Our mitochondrial health page explains the biology further. Crucially, this is a metabolic pathway — it does not act on estrogen or any reproductive hormone.

The human evidence, organized by strength

Here is what has actually been measured in people. Note as you read: participants were older adults and middle-aged adults — not a perimenopause-specific group — so apply these findings to yourself thoughtfully rather than assuming they transfer directly.

Established human findings

The first-in-human study, Andreux and colleagues (2019, Nature Metabolism), showed urolithin A was safe and well tolerated at up to 1,000 mg per day and produced a mitochondrial gene-expression signature in participants. In 2022, Liu and D'Amico and colleagues (JAMA Network Open) found improved muscle endurance — more muscle contractions before fatigue — in older adults over roughly four months. Also in 2022, Singh and colleagues (Cell Reports Medicine) reported improvements in muscle strength and exercise performance in middle-aged adults using 500 mg and 1,000 mg daily. These middle-aged and older adult trials are the closest the evidence comes to the age range many perimenopausal women are in — though they were not designed around menopausal status.

Newer human findings

A 2025 randomized trial in Nature Aging found urolithin A supported the mitochondrial health of immune cells in midlife adults, relevant to the low-grade inflammation of aging sometimes called inflammaging. A 2024 eight-week randomized trial in the Journal of the International Society of Sports Nutrition looked at endurance and recovery markers in resistance-trained men, and a 2025 trial studied distance runners. You can see all of these in our clinical studies summary and urolithin A for muscle page.

The essential limitation, stated by a 2024 systematic review in Ageing Research Reviews: the human evidence is still emerging, with short trials and modest sample sizes. And none of these trials were perimenopause-specific. So the fair reading is that urolithin A has promising human data on muscle and cellular energy in adults broadly — which may be relevant to midlife women, but has not been proven in them.

The preclinical background

The foundational work is animal and cell research — mechanism, not human proof. Ryu and colleagues (2016, Nature Medicine) first showed urolithin A induced mitophagy, extended lifespan in C. elegans, and improved muscle function in rodents. Separately, D'Amico and colleagues (2022, Aging Cell) explored joint and cartilage mitochondrial health in osteoarthritis models — an early, preclinical signal in a tissue relevant to midlife joint comfort, but again animal-model work, not human proof. Early or preclinical research is also exploring urolithin A in other tissues; none of it reaches the level of human evidence in perimenopausal women.

Where this fits alongside real perimenopause care

This is not a treatment — and this point matters a great deal here. Perimenopause deserves real medical care. Hot flashes, sleep disruption, mood changes, irregular or heavy bleeding, bone health, cardiovascular risk, and low energy all have evidence-based options — including, for many women, menopausal hormone therapy — that only a clinician can tailor to you. Urolithin A does not replace any of that. It is not a hormone, does not treat menopausal symptoms, and should never be a reason to delay talking to your doctor or gynecologist. Please have that conversation; a supplement is at most a small supporting piece, never the plan.

Within a doctor-guided approach, the foundations that most reliably protect midlife muscle and energy are resistance training, adequate protein, sufficient sleep, and managing stress. Urolithin A is best thought of as a possible add-on to support the cellular-energy side of muscle — not a substitute for the fundamentals or for medical care. Our urolithin A for energy page goes deeper on the energy question specifically.

Practical guidance

The clinically studied range is 500–1,000 mg of urolithin A per day, with 1,000 mg at the top of that range. Effects build over weeks of consistent daily use rather than being felt from a single dose — our how long urolithin A takes to work page explains the realistic timeline, and how to take urolithin A covers the routine. If you take any medication or have a health condition, clear it with your doctor or pharmacist first.

SOMA HEALTH Urolithin A Gummies deliver 1,000 mg per four-gummy daily serving — the top of the clinically studied range — sugar-free, raspberry-flavored, and third-party tested, with 120 gummies for a 30-day supply. If you are comparing products, our best urolithin A gummies guide walks through what to look for.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.